Welcoming Daniel J. Wallace, MD to Lupus Therapeutics
The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel J. Wallace, MD joins as a new member of its distinguished Board of Directors. A renowned leader in clinical research and care for lupus and other rheumatologic diseases, Dr. Wallace is Medical Director of the Wallace Rheumatic Study Center and Associate […]
Dr. Daniel Wallace Appointed to Lupus Therapeutics Board
New York, NY, July 18, 2019 — Renowned Dr. Daniel Wallace joined the Lupus Research Alliance (LRA) affiliate Lupus Therapeutics Board of Directors. This governing body, which includes lupus patients, family members and scientists, provides strategic insight and financial oversight to help Lupus Therapeutics achieve its mission –accelerate new ways to diagnose and treat lupus.
Board of Directors
Angelica Perez Finds a Simple Way to Make a Huge Difference – You Can Too!
Participating in the LRA’s Lupus Landmark Study was a “no-brainer” says Angelica Perez, a 37-year-old woman living with lupus since she was nine. “I had been taking part in clinical trials for years to potentially improve my own care while helping to advance new treatments overall.” A patient of renowned Los Angeles lupus physician and […]
Lupus Therapeutics, Affiliate of Lupus Research Alliance, Developing a Study Focused on Lupus Patients and COVID-19
New York, NY, April 7, 2020 – Lupus Therapeutics, the clinical trial affiliate of the Lupus Research Alliance (LRA), announced today that it is embarking on a clinical study to assess the potential benefit of hydroxychloroquine and/or other lupus therapies in preventing or reducing the symptoms of COVID-19 in people with lupus. The study […]
Lupus Therapeutics, filial de Lupus Research Alliance, desarrolla un estudio que se enfoca en los pacientes con lupus y la COVID-19
7 de abril de 2020 Nueva York, NY, 7 de abril de 2020 – Lupus Therapeutics, la filial de ensayos clínicos de Lupus Research Alliance (LRA), anunció hoy que está iniciando un estudio clínico para evaluar el posible beneficio de la hidroxicloroquina u otras terapias para el lupus con el fin de evitar o […]
ACR|ARHP News on Potential New Lupus Treatments
October 25, 2018 The Lupus Research Alliance was on the ground at the American College of Rheumatology 2018 meeting to bring you the latest news in lupus research and translation. Several clinical trials showed benefits of potential new treatments for helping people with lupus. Following are summaries of the stand-out results: Ustekinumab (Stelara®) A Phase 2 […]
Study Shows Kidney Transplant Improves Lupus Nephritis Survival
January 21, 2019 A study just published in Annals of Internal Medicine showed that kidney transplantation reduced deaths due to lupus nephritis — kidney inflammation caused by lupus. Up to 60 percent of people with SLE are diagnosed with lupus nephritis, which can lead to significant illness and even death. According to the National Institute of Diabetes […]
Patients with Lupus Nephritis-Related Kidney Disease Are Living Longer
March 28, 2019 A new study published this March in Arthritis & Rheumatology found that deaths among patients with end-stage renal disease (ESRD) due to lupus nephritis (LN) fell significantly — by 32% —over the past two decades. The study took into account deaths from all causes, including deaths from cardiovascular disease (CVD) and infection. […]
New Study Shows Active Epstein-Barr Virus Increases Chance for Lupus in At-Risk People
August 13, 2019 New research results showed that active Epstein-Barr virus increases the risk for lupus among relatives of people who already have lupus. Epstein-Barr virus is one of the most common human viruses. After the first infection, the virus becomes inactive in your body and can reactivate at any time. Scientists have known that […]
MARCH 26 STATEMENT: Lupus Research Alliance Puts Plaquenil (Hydroxychloroquine) Shortage into Perspective for Lupus Community
March 26, 2020 The Lupus Research Alliance (LRA), the world’s leading research organization dedicated to lupus research, continues to watch rapidly changing developments regarding COVID-19 and is closely monitoring the policies and actions of the federal government, healthcare agencies, medical organizations and the pharmaceutical industry on behalf of people with lupus. Thrust into the spotlight […]
DECLARACIÓN DEL 26 DE MARZO: La Alianza para la investigación de Lupus pone en perspectiva la escasez de Plaquenil (hidroxicloroquina) para la comunidad con lupus
26 de marzo de 2020 La Alianza para la investigación de Lupus (LRA), la principal organización de investigación del mundo dedicada a la investigación del lupus, continúa observando rápidamente los cambios en relación con la COVID-19 y está controlando de cerca las políticas y acciones del gobierno federal, las agencias de atención médica, las organizaciones […]